A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation
OPEN TO ACCRUAL
III
NCT07211958
AChergui@brownhealth.org
